EPC-006

N/A

Report date: 2025/02/14 17:13:12

Base Information

Drug NameEPC-006

Drug Alias NameEPC-006

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD276

TargetsCD276 antigen

Therapy Area/IndicationsLung Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesElpis BioPharmaceuticals Corp

China Registration ClassN/A

Develop Information

Active CompaniesElpis BioPharmaceuticals Corp

Inactive CompaniesN/A

Active IndicationsLung Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A